AS ADJUNCTIVE THERAPY IN LIFE THREATENING CONDITIONS
The recommended dose of SOLU-MEDROLÖ Sterile Powder (methylprednisolone sodium succinate) is 30 mg per kg given I.V. over a period of at least 30 minutes. This dose may be repeated every 4-6 hours for up to 48 hours.
PULSE DOSING for corticosteroid responsive diseases in exacerbation and/or unresponsive to standard therapy (e.g. lupus nephritis, rheumatoid arthritis, etc.).
Suggested schedules:
Rheumatoid arthritis: 1 g/day I.V. for 1, 2, 3 or 4 days I.V. or 1 g/month for 6 months I.V.
Systemic lupus erythematosus:
1 g/day for 3 days I.V.
Multiple sclerosis:
1 g/day for 3 days I.V. or 1 g/day for 5 days I.V.
Edematous states, e.g.: glomerulonephritis, lupus nephritis: 30 mg/kg every other day for 4 days I.V. or 1 g/day for 3, 5 or 7 days I.V.
The regimen should be administered over at least 30 minutes and may be repeated if improvement has not occurred within a week after therapy or as patient’s condition dictates.
TERMINAL CANCER - QUALITY OF LIFE
Prospective, controlled studies have shown that SOLU-MEDROLÖ Sterile Powder 125 mg administered intravenously daily for up to 8 weeks, significantly improves quality of life in patients with terminal cancer.
PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY
Suggested schedules:
Mild to moderately emetogenic chemotherapy:
Administer SOLU-MEDROLÖ Sterile Powder 250 mg I.V. over at least 5 minutes one hour before chemotherapy, at the initiation of chemotherapy and at the time of discharge. A chlorinated phenothiazine may also be used with the first dose of SOLU-MEDROLÖ Sterile Powder for increased
effect.
Severely emetogenic chemotherapy:
Administer SOLU-MEDROLÖ Sterile Powder 250 mg I.V. over at least 5 minutes with appropriate doses of metoclopramide or a butyrophenone one hour before chemotherapy, then SOLU-MEDROLÖ Sterile Powder 250 mg I.V. at the initiation of chemotherapy and at time of discharge.
IN OTHER INDICATIONS, initial dosage will vary from 10 to 500 mg depending on the clinical problem being treated. Larger doses may be required for short-term management of severe, acute conditions. The initial dose, up to 250 mg, should be given intravenously over a period of at least 5 minutes, and if greater than 250 mg, should be given over at least 30 minutes. Subsequent doses may be given intravenously
or intramuscularly at intervals dictated by the patient’s response and clinical condition.
Corticosteroid therapy is an adjunct to, and not replacement for, conventional therapy. Dosage may be reduced for infants and children but should be governed more by the severity of the condition and response of the patient than by age or size. It should not
be less than 0.5 mg per kg every 24 hours. SOLU-MEDROLÖ Sterile Powder may be administered by intravenous or intramuscular injection or by intravenous infusion, the preferred method for initial emergency use
being intravenous injection. To administer by intravenous (or intramuscular) injection,prepare solution as directed.
|